Paul Tiger > Freshfields Bruckhaus Deringer LLP > New York, United States > Lawyer Profile

Freshfields Bruckhaus Deringer LLP
601 LEXINGTON AVENUE
31ST FLOOR
NEW YORK, NY 10022
NEW YORK
United States

Work Department

Corporate

Position

Corporate and M&A Partner

Career

Paul advises on complex public and private M&A transactions and private equity investments.

Paul also has deep experience with de-SPAC transactions and PIPE financings.

Both in connection with and separate from these transactions, he counsels companies and their boards on stockholder activism, corporate governance, and fiduciary duty considerations. Paul has been recognized as a Dealmaker of the Year by The American Lawyer (2023), among the 500 leading dealmakers in the United States by Lawdragon 500 (2021, 2022), as a rising star for M&A by Law360, and among leading lawyers for M&A and activism by Legal 500 and M&A by IFLR1000. 

Memberships

Member of the New York State bar and the Oregon State Bar Certified Public Accountant (inactive).

Education

Stanford Law School, J.D. with distinction; Order of the Coif 2004

University of Oregon, B.A. summa cum laude 1999

Lawyer Rankings

United States > M&A/corporate and commercial > M&A: large deals ($1bn+)

Acting for the likes of international pharma corporations, tech providers, and energy conglomerates, the Freshfields Bruckhaus Deringer LLP team comprises a set of corporate specialists who cover matters ranging from cross-border transactions to takeover defense. Ethan Klingsberg and Damien Zoubek co-head the New York offering, with the former routinely advising special committees and boards of directors on impactful mergers and complex governance issues, while the latter is an expert on shareholder activism defense. Also in New York, Jenny Hochenberg frequently tackles transformative M&A transactions, Sebastian Fain is knowledgeable on joint ventures, and both Paul Tiger and Paul Humphreys focus on stockholder activism and all-stock mergers. Based in San Francisco, John Fisher has expertise in the life sciences sector, while Joseph Halloum concentrates on IPOs and SPAC transactions.